Compare JBSS & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JBSS | REPL |
|---|---|---|
| Founded | 1959 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 839.3M | 721.7M |
| IPO Year | 1991 | 2018 |
| Metric | JBSS | REPL |
|---|---|---|
| Price | $72.68 | $10.45 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $109.00 | $12.00 |
| AVG Volume (30 Days) | 54.8K | ★ 1.9M |
| Earning Date | 01-28-2026 | 11-06-2025 |
| Dividend Yield | ★ 3.43% | N/A |
| EPS Growth | ★ 21.12 | N/A |
| EPS | ★ 5.62 | N/A |
| Revenue | ★ $1,129,733,000.00 | N/A |
| Revenue This Year | $5.40 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.97 | ★ N/A |
| Revenue Growth | ★ 1.88 | N/A |
| 52 Week Low | $58.47 | $2.68 |
| 52 Week High | $91.98 | $14.80 |
| Indicator | JBSS | REPL |
|---|---|---|
| Relative Strength Index (RSI) | 65.13 | 67.37 |
| Support Level | $71.06 | $9.35 |
| Resistance Level | $73.15 | $11.09 |
| Average True Range (ATR) | 1.55 | 0.62 |
| MACD | -0.08 | 0.02 |
| Stochastic Oscillator | 80.46 | 69.90 |
John B Sanfilippo & Son Inc is one of the processors and distributors of peanuts, pecans, cashews, walnuts, almonds, and other nuts in the United States. These nuts are sold under a variety of private brands and the Fisher, Orchard Valley Harvest, and Sunshine Country brand names. It also markets and distributes, and in the majority of cases, manufactures or processes, a diverse product line of food and snack products, including peanut butter, almond butter, cashew butter, candy and confections, snacks and trail mixes, snack bites, sunflower kernels, dried fruit, corn snacks, sesame sticks and other sesame snack products under private brands and brand names.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.